Not for release, Publication or Distribution in whole or in part in or into the United States, Canada or Japan. This is an advertisement for information purposes only. This is not a Prospectus announcement, and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. Not for publication or distribution, directly or indirectly outside India.

**ALKEM LABORATORIES LIMITED**

Alkem Laboratories Limited ("Company") was incorporated as a private limited company 'Alkem Laboratories Private Limited' on August 8, 1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43(2) of Companies Act, 1956 on October 26, 1988. Pursuant to the passing of a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of Incorporation consequent on change of name dated August 21, 2001, the name of our Company was changed to 'Alkem Laboratories Limited' with effect from October 26, 1988. Pursuant to an order passed by the Company Law Board, Kolkata, the registered office of our Company was shifted from state of Bihar to Maharashtra in the year 2007. For further details, please refer to the chapter "History and Certain Corporate Matters" on page 158 of the Red Herring Prospectus dated November 27, 2015 ("RHP").

Registered Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400 013, Maharashtra, India. Tel No: +91 22 3982 9999; Fax No: +91 22 2492 7190. Contact Person: Mr. Manish Narang, Senior Vice President, Legal, Company Secretary and Compliance Officer; Tel No: +91 22 3982 9999; Fax No: +91 22 2492 7190. E-mail: investors@alkem.com. Website: www.alkemlabs.com. Corporate Identity Number: U00305MH1973PLC174211.

**APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA):** Investors may apply through the ASBA process. ASBA can be availed by all the investors except Anchor Investors. Non-retail investors i.e. QIBs and Non-Institutional Bidders, have to compulsorily apply through ASBA to participate in the Offer. The investor is required to fill the Bid cum Application Form and submit the same to the relevant SCB or to the Broker Members at the Specified Locations or the Brokered Brokers at Broker Centres. The SCB will block the amount in the account as per the authority contained in the Bid cum Application Form. On Allotment, amount will be unblocked and account will be debited only to the extent required to be paid for Allotment of Equity Shares. Hence, there will be no need for refunds. Bid cum Application Forms can also be downloaded from the websites of the Stock Exchanges. Bid cum Application members of the syndicate or can be obtained from the list of SCBs that is available on the website of SEBI at http://www.sebi.gov.in/sebiweb/home/lst/533/0/Recognised-Intermediaries. For details about ASBA, please refer to the details given in Bid cum Application Form and Abridged Prospectus and the section "Offer Procedure" beginning on page 482 of the RHP.

**Contents of the Memorandum of the company as regards its Objects:** Investors are requested to refer to clause 13 of the Memorandum of Association of the company for the main objects and other objects of the company. The Memorandum of Association of the company is a material document for inspection in relation to the Issue. For details, see the section "Material Contracts and Documents for Inspection" on page 555 of the RHP.

**Outstanding Litigation and Material Developments**

Our Company has the right to appeal this decision before the Competition Appellate Tribunal within 60 days from receipt of the final order under the provisions of the Competition Act. Our Company is in the process of seeking legal advice to challenge the Order before the Competition Appellate Tribunal on merits. Our Company also does not anticipate any changes to its distribution arrangements. As liability involved in said matter was not ascertainable at the time of filing the RWP with ROC, the same has not been considered for our Financial Statements included in the RHP.

**ADDENDUM - NOTICE TO INVESTORS**

Our Company has filed the RHP in relation to the Offer with the Registrar of Companies, Maharashtra at Mumbai ("ROC"). All capitalised terms used in this Addendum to the RHP, Bid-cum-Application Forms and the Abridged Prospectus ("Addendum") shall, unless the context otherwise requires, have the meanings ascribed in the RHP. Investors may please note that the following disclosures supplement the disclosures in the RHP.

Our Company had disclosed in the chapter "Outstanding Litigation and Material Developments", under the heading "Proceedings before the Competition Commission of India ("CCI")", on page 404 - 405 of the RHP.

We wish to inform you that CCI has by way of its order dated December 1, 2015 ("Order") imposed a penalty of ₹746.3 million under section 27 of the Competition Act for contravention of section 3(1) of the Competition Act, for facilitating the acts of All Kerala Chemists and Druggists Association and its officials for the anti-competitive conduct.

The Company has the right to appeal this decision before the Competition Appellate Tribunal within 60 days from receipt of the final order under the provisions of the Competition Act. Our Company is in the process of seeking legal advice to challenge the Order before the Competition Appellate Tribunal on merits. Our Company also does not anticipate any changes to its distribution arrangements. As liability involved in said matter was not ascertainable at the time of filing the RWP with ROC, the same has not been considered for our Financial Statements included in the RHP.

The RWP shall be supplemented to the extent stated hereinabove and the above notice is required to be read in conjunction with other disclosures in the RHP. The chapters "Risk Factors" and "Outstanding Litigation and Material Developments" in the Prospectus, to be filed with the ROC shall be suitably amended to reflect the aforementioned update.

The above notice is required to be read in conjunction with the RHP, the Bid-cum-Application Forms and the Abridged Prospectus dated November 27, 2015.

For ALKEM LABORATORIES LIMITED

On behalf of the Board of Directors

Sd/-

Senior Vice President, Legal, Company Secretary and Compliance Officer

Date: December 5, 2015

Alkem Laboratories Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the RHP with the Registrar of Companies, Maharashtra, Mumbai. The RHP shall be available on the website of SEBI at www.sebi.gov.in, the websites of the Stock Exchanges and the website of the GCBRLMs at www.nmurholdings.com/company/group/asia/india/index.html, www.axiscapital.co.in, www.jpmipl.com and www.edelweissfin.com. Any Potential Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" on page 18 of the RHP. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.